Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications. The company also develops MDG2011, MDG2021, MDG2012, MDG20XX, and MDG10xx to treat multiple solid tumors. It has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company has a research collaboration agreement with WuXi Biologics to design and co-research TCR-guided T Cell engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors; and strategic co-development agreement with EpimAb Biotherapeutics, Inc. to research and develop off-the-shelf TCR-guided T Cell Engagers for the treatment of immune-related disorders, such as solid tumors. Medigene AG was founded in 1994 and is headquartered in Munich, Germany.